Future role of BTK degraders in CLL treatment скачать в хорошем качестве

Future role of BTK degraders in CLL treatment

Justin Taylor, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, discusses how BTK degraders may be integrated into treatment sequencing for chronic lymphocytic leukemia (CLL). He explores their emerging role in relapsed/refractory CLL, their potential to complement or replace existing BTK inhibitors, and how ongoing trials may shape their use in earlier lines of therapy over the next decade. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.